Enterocolitis, Pseudomembranous: Clinical Trials

9 trials for Enterocolitis, Pseudomembranous, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

9 completed. 9 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 29Completed 9

Follow Enterocolitis, Pseudomembranous: new trials by email Literature Review of Enterocolitis, Pseudomembranous trials Research Report on Enterocolitis, Pseudomembranous

Trials (filtered) newest first · largest first

All 9 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Multicentre Blinded Comparison of Lyophilized Sterile Fecal Filtrate to Lyophilized Fecal Microbiota Transplant in Recurrent Clostridioides Difficile Infection
Lyophilized fecal microbiota transplant, Lyophilized sterile fecal filtrate - Clostridia Difficile Colitis, Clostridium Difficile Diarrhea
Phase 2CompletedUniversity of Alberta1382019-03-212024-06-04
Efficacy of Oral Vancomycin Prophylaxis for Prevention of Recurrent Clostridium Difficile Infection
Vancomycin, Placebo - Recurrent Clostridium Difficile Infection, Clostridium Difficile Infection
Phase 2CompletedUniversity of Wisconsin, Madison792018-05-212025-05-25
Fecal Microbiota Transplantation for Severe Clostridium Difficile Infection
Single-infusion FMT, Vancomycin (before randomization), multiple-infusion FMT - Clostridium Difficile, Pseudomembranous Colitis
Phase 2CompletedCatholic University of the Sacred Heart582016-03-012018-02-09
Transplantation of Cultured Gut Microflora to Repeat Antibiotic-induced Diarrhea Due to Clostridium Difficile
Cultured human intestinal microbiota, Vancomycin, Metronidazole - Clostridium Difficile
Phase 2CompletedPer Hellström602014-10-012019-01-09
Stool Transplant in Pediatric Patients With Recurring C. Difficile Infection
FMT, placebo - Clostridium Difficile Colitis
Phase 2CompletedMemorialCare Health System92013-10-012016-09-01
Safety and Efficacy of Multiple Daily Dosing of Oral LFF571 in Patients With Moderate Clostridium Difficile Infections
LFF571, Vancomycin (POC) - Moderate Clostridium Difficile Infection
Phase 2CompletedNovartis Pharmaceuticals1092010-10-012020-12-19
Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults
Clostridium difficile toxoids A and B (Low-dose with adjuvant), Clostridium difficile toxoids A and B (Low-dose without adjuvant), Clostridium difficile toxoids A and B (high-dose with adjuvant) - Clostridium Difficile Infection, Diarrhea
Phase 2CompletedSanofi Pasteur, a Sanofi Company6502010-10-012018-07-18
A Study of the Absorption of GT267-004 in Patients With Clostridium Difficile-Associated Diarrhea
tolevamer potassium-sodium (GT267-004) - Pseudomembranous Colitis, Clostridium Difficile Diarrhea
Phase 2CompletedGenzyme, a Sanofi Company242006-09-012015-03-19
A Study of GT160-246 Versus Vancomycin in Patients With Clostridium Difficile-Associated Diarrhea
GT160-246 - Clostridium Difficile-Associated Diarrhea, Clostridium Enterocolitis
Phase 2CompletedGenzyme, a Sanofi Company3002002-02-012015-03-05

Narrower conditions

Clostridium Infections (3)  ·  Dysentery (2)  ·  Diarrhea (1)

Broader conditions

Bacterial Infections (9)  ·  Bacterial Infections and Mycoses (9)  ·  Digestive System Diseases (9)  ·  Enterocolitis (9)  ·  Gastroenteritis (9)  ·  Gastrointestinal Diseases (9)  ·  Gram-Positive Bacterial Infections (9)  ·  Infections (9)  ·  Intestinal Diseases (9)  ·  Clostridium Infections (6)  ·  Pathological Conditions, Signs and Symptoms (1)  ·  Signs and Symptoms (1)  ·  Signs and Symptoms, Digestive (1)

Interventions

Vancomycin (4)  ·  Adjuvants, Pharmaceutic (1)  ·  Fecal Microbiota Transplantation (1)  ·  Fluoridation (1)  ·  LFF571 (1)  ·  Metronidazole (1)  ·  Saline Solution (1)  ·  Sodium Chloride (1)  ·  styrenesulfonic acid polymer (1)

Sponsors

Genzyme, a Sanofi Company (2)  ·  Catholic University of the Sacred Heart (1)  ·  MemorialCare Health System (1)  ·  Novartis Pharmaceuticals (1)  ·  Per Hellström (1)  ·  Sanofi Pasteur, a Sanofi Company (1)  ·  University of Alberta (1)  ·  University of Wisconsin, Madison (1)

Countries

United States (5)  ·  Canada (4)  ·  Puerto Rico (1)  ·  Sweden (1)  ·  United Kingdom (1)

Top investigators

Dina Kao, MD (1)  ·  Nasia Safdar, MD PhD (1)  ·  Sonia Michail, MD (1)

Results publications

PMID 10440607, PMID 11171619, PMID 21871249, PMID 23323867, PMID 25534724, PMID 25534727, PMID 27013431, PMID 29851107, PMID 31537446, PMID 40601321, PMID 40997843, PMID 9712236